Salim K. Mujais

Nephrology

1 Astellas Way
Northbrook, IL 60062

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Bladder Function and Safety of Vibegron in Men With Overactive Bladder Receiving Treatment for Benign Prostatic Hyperplasia: Outcomes From the Phase 3 Randomized Controlled COURAGE Trial.

Bladder Function and Safety of Vibegron in Men With Overactive Bladder Receiving Treatment for Benign Prostatic Hyperplasia: Outcomes From the Phase 3 Randomized Controlled COURAGE Trial.

Journal: Neurourology and urodynamics

Published: May 19, 2025

Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE Trial.

Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE Trial.

Journal: Urology

Published: May 08, 2025

Gene Therapy With URO-902 (pVAX/hSlo) for the Treatment of Female Patients With Overactive Bladder and Urge Urinary Incontinence: Safety and Efficacy From a Randomized Phase 2a Trial.

Gene Therapy With URO-902 (pVAX/hSlo) for the Treatment of Female Patients With Overactive Bladder and Urge Urinary Incontinence: Safety and Efficacy From a Randomized Phase 2a Trial.

Journal: The Journal of urology

Published: December 18, 2024

Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial.

Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial.

Journal: The Journal of urology

Published: May 06, 2024

Commentary on: Pharmacist-driven interventions to de-escalate urinary antimuscarinics in the Program of All-Inclusive Care for the Elderly.

Commentary on: Pharmacist-driven interventions to de-escalate urinary antimuscarinics in the Program of All-Inclusive Care for the Elderly.

Journal: Journal of the American Geriatrics Society

Published: February 16, 2023

Comment on: Pharmacist-driven interventions to de-escalate urinary antimuscarinics in the Programs of All-Inclusive Care for the Elderly.

Comment on: Pharmacist-driven interventions to de-escalate urinary antimuscarinics in the Programs of All-Inclusive Care for the Elderly.

Journal: Journal of the American Geriatrics Society

Published: November 04, 2022

Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.

Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.

Journal: Antimicrobial agents and chemotherapy

Published: May 18, 2017

QT Interval Shortening With Isavuconazole: In Vitro and In Vivo Effects on Cardiac Repolarization.

QT Interval Shortening With Isavuconazole: In Vitro and In Vivo Effects on Cardiac Repolarization.

Journal: Clinical pharmacology and therapeutics

Published: January 04, 2017

Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.

Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.

Journal: European journal of clinical pharmacology

Published: October 14, 2016

Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment.

Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment.

Journal: Antimicrobial agents and chemotherapy

Published: December 08, 2015

Comparison of the safety, tolerability, and pharmacokinetics of fidaxomicin in healthy Japanese and caucasian subjects.

Comparison of the safety, tolerability, and pharmacokinetics of fidaxomicin in healthy Japanese and caucasian subjects.

Journal: Clinical drug investigation

Published: May 15, 2015

The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials.

The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials.

Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Published: December 17, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026